本地临床试验:改善全球癌症治疗的迫切需要

IF 0.3 Q4 ONCOLOGY

Indian Journal of Medical and Paediatric Oncology Pub Date : 2023-09-28 DOI:10.1055/s-0043-1768568

Apar Kishor Ganti

{"title":"本地临床试验:改善全球癌症治疗的迫切需要","authors":"Apar Kishor Ganti","doi":"10.1055/s-0043-1768568","DOIUrl":null,"url":null,"abstract":"Advances in the care of cancer patients are almost always due to clinical trials that demonstrate improved patient outcomes in terms of better survival or improved quality of life. Pharmaceutical companies invest a large amount of time, effort, and money in developing novel agents, but only a few of these end up actually changing patient care. Agents such as imatinib, osimertinib, trastuzumab, rituximab, and pembrolizumab, among others, are prime examples of this approach. A recent analysis found that the median cost of development of an anticancer drug was $648.0 million.[1]","PeriodicalId":13513,"journal":{"name":"Indian Journal of Medical and Paediatric Oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Local Clinical Trials: The Need of the Hour to Improve Global Cancer Care\",\"authors\":\"Apar Kishor Ganti\",\"doi\":\"10.1055/s-0043-1768568\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advances in the care of cancer patients are almost always due to clinical trials that demonstrate improved patient outcomes in terms of better survival or improved quality of life. Pharmaceutical companies invest a large amount of time, effort, and money in developing novel agents, but only a few of these end up actually changing patient care. Agents such as imatinib, osimertinib, trastuzumab, rituximab, and pembrolizumab, among others, are prime examples of this approach. A recent analysis found that the median cost of development of an anticancer drug was $648.0 million.[1]\",\"PeriodicalId\":13513,\"journal\":{\"name\":\"Indian Journal of Medical and Paediatric Oncology\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Medical and Paediatric Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0043-1768568\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical and Paediatric Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1768568","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症患者护理的进步几乎总是源于临床试验，这些试验证明了患者在更好的生存或生活质量方面的改善。制药公司投入了大量的时间、精力和金钱来开发新型药物，但最终真正改变患者护理的只有少数。诸如伊马替尼、奥西替尼、曲妥珠单抗、利妥昔单抗和派姆单抗等药物是这种方法的主要例子。最近的一项分析发现，开发一种抗癌药物的平均成本为6.48亿美元。[1]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Local Clinical Trials: The Need of the Hour to Improve Global Cancer Care

Advances in the care of cancer patients are almost always due to clinical trials that demonstrate improved patient outcomes in terms of better survival or improved quality of life. Pharmaceutical companies invest a large amount of time, effort, and money in developing novel agents, but only a few of these end up actually changing patient care. Agents such as imatinib, osimertinib, trastuzumab, rituximab, and pembrolizumab, among others, are prime examples of this approach. A recent analysis found that the median cost of development of an anticancer drug was $648.0 million.[1]

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Medical and Paediatric Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： The journal will cover technical and clinical studies related to medical and pediatric oncology in human well being including ethical and social issues. Articles with clinical interest and implications will be given preference.